# HSEF v5.3 review: Lifestyle Weight Loss and MASH Reversal

> Sources: 61 primary reports; claims: 66; verified: 66; unverified: 0. Verification is bounded attribution. Access: 3 partial-body and 58 bounded abstract/status examinations. Literature cutoff: 2026-10-13; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed.

> **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 5 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Second independent adversarial pass by Claude Opus 5.5 (Anthropic) on 2026-11-02: 8 corrections applied (WL-1 to WL-8; see SECOND ADVERSARIAL PASS). Status: **Approved as revised.**

## AT A GLANCE

**Lifestyle treatment can improve MASH histology; fibrosis reversal, liver-death prevention and weight loss as the sole mediator require stronger direct evidence.**

| Level | Confidence | Causal role | Momentum | Stability | Divergence |
|---|---|---|---|---|---|
| Δ — First field-valid causal perturbation crossed | Moderate | reinforcing / stabilizing factor | Mechanistic only | Stable | Contested |

**Deciding experiment:** A multicentre lifestyle-versus-matched-support randomized trial enrolls baseline-biopsy MASH adults, stratifies fibrosis stage and diabetes before outcomes, and measures independently read paired inflammation/ballooning resolution at 52–104 weeks. Factorial diet/exercise and prospectively controlled energy/weight trajectories distinguish package efficacy from isolated mediator claims; retain all assigned participants and specify missing-biopsy sensitivity analyses. Extend blinded hepatic event follow-up.

**Belief versus evidence:** The registered primary SC2 reaches Δ with Moderate confidence: a small randomized lifestyle package changes explicit steatohepatitis histology, while the older trial offers broader activity support. Direct original-body examination prevents calling fat-only NAS changes full resolution. Evidence does not yet map sufficiently broad baseline contexts or isolate achieved weight as the causal mediator to reach Ε or mechanistically narrowed convergence. Separate Γ fibrosis and surrogate-to-event companions do not erase the positive registered clinical phenotype.

**Best-supported rival:** Fat, inflammation and fibrosis have distinct treatment responses (tournament rank 1; non-nominal); Δ. Actual Promrat body PMID19827166 separates significant assigned NAS/steatosis change from nonsignificant assigned inflammation/ballooning and fibrosis. PMID38914313 supplies a newer explicit activity/resolution positive with unchanged average fibrosis. These contrasts favor component-specific response over a single universal weight-to-all-liver-outcomes mechanism. The review’s own nominal model — energy balance and adiposity change reverse steatohepatitis — is ranked 2 in the tournament and is not the rival.

## COMPETING MECHANISTIC MODELS

**Rank 2: Energy balance and adiposity change reverse steatohepatitis (Δ).** Lifestyle packages change metabolic input and can improve active histology. The newer histology trial and older assigned NAS/steatosis trial establish genuine package effects. Weight-histology correlations do not isolate the mediator; fibrosis and several component or comparator endpoints remain null. The randomized standard-care-controlled paired-biopsy trial of Eckard 2013 [61] found improvement in every arm without a between-arm difference.

**Rank 1: Fat, inflammation and fibrosis have distinct treatment responses (Δ).** Pathological components respond differently to lifestyle, activity and drugs. Promrat has fat/NAS positives but assigned component and fibrosis nulls; the newer trial has activity benefit without average fibrosis improvement, and the F4 drug trial has fat/weight benefit without histologic resolution. This is a component-response model, not proof of one unique upstream molecular pathway or inevitable irreversibility.

**Rank 3: Achieved loss and host adherence confound mediator attribution (Γ).** Baseline biology and adherence affect achieved loss and histologic response together. Uncontrolled achieved-at-least-10% cohorts and posthoc drug-responder analyses cannot isolate kilograms from cointerventions. Confounding of achieved loss does not explain away randomized lifestyle-package contrasts.

**Rank 4: Baseline stage and intervention identity determine transfer (Γ).** Established fibrosis, cirrhosis and direct drug action differ from earlier active disease and lifestyle input. Noncirrhotic drug positives, F4 semaglutide nulls and surgery results map exposure/stage boundaries. Cross-trial differences do not prove a treatment-by-stage interaction or establish every stage-specific lifestyle effect.

**Rank 5: Non-specific trial effects, regression to the mean and biopsy sampling variability explain small-trial histologic change (Γ).** Control and standard-care arms also improve; single-pathologist small samples and completer analyses magnify noise. Randomized between-arm differences in [1] and [46] are not explained by this, but the null between-arm contrast in Eckard 2013 [61] is.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

## FULL REVIEW

### Registered claim and scope

Lifestyle-mediated weight loss reverses steatohepatitis in adults with baseline biopsy-confirmed MASH.

Evaluated wording: Assigned lifestyle weight-loss treatment improves steatohepatitis histology in adults with baseline biopsy-confirmed MASH over 24–104 weeks. This makes the preregistered primary SC2 assignment estimand explicit. It preserves inflammation/ballooning rather than fat alone, the baseline MASH population and follow-up. It does not claim that achieved kilograms independently mediate every response, that all patients respond, or that fibrosis and liver-death prevention have been established.

The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint.

Selection: position 15 in the registered editorial traffic-priority list; registration timestamp 2026-10-13T16:06:25.313824+00:00. Ranked editorial traffic priority rather than measured global popularity or a preset verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

### Evidence and causal interpretation

Rubric fit: The frozen framework has no dedicated clinical hepatology rubric. Rubric 06 governs proxy-versus-phenotype interpretation with an explicit clinical adaptation: an assigned treatment changing paired steatohepatitis pathology is a disease phenotype perturbation, rather than an aging/lifespan claim. Literal caps and ladder remain unchanged. A biopsy fat component is scored as its own measured pathology in SC1, not as full MASH clinical success. Human treatment assignment establishes package sufficiency, not necessity or endogenous weight-mediated disease primacy.

The primary distinction is assigned treatment versus achieved weight. Promrat randomized a lifestyle package and observed NAS/steatosis improvement. Its actual Results say assigned inflammation and ballooning contrasts were not significant and fibrosis did not change. The positive achieved-at-least-7% component strata are informative but nonrandomized. Its NAS-based minimal-criteria response cannot automatically substitute for current MASH resolution.

The newer small lifestyle trial explicitly requires inflammation 0–1 and ballooning 0 for resolution and reports improvements in inflammation, ballooning and steatohepatitis after about ten months of energy restriction and supervised HIIT. Average fibrosis remains unchanged. Results report resolution of steatohepatitis in 9 treatment and 0 control participants (final sample 16 and 8; the Discussion gives 56%). Eight treated participants *reduced* ballooning to 0; this is compatible with nine resolutions, because inclusion required NAS of at least 4 rather than ballooning of at least 1, so a participant could enter with ballooning 0. The counts are reconcilable, not inconsistent. The real caveats are that component reductions are reported within the treatment arm, the text prints no between-group test for resolution or components, and control participants entered with higher MRS liver fat (24% versus 15%), which the authors say may have contributed to the difference.

The large lifestyle cohort found resolution and fibrosis regression among paired biopsies and a striking achieved-at-least-10% pattern. This is not a randomized ≥10% versus <10% intervention, nor is it a baseline-defined scope. Shared prediction and renal follow-ups remain one cohort. The evidence supports a dose-related clinical association while leaving adherence, baseline host biology and cointerventions plausible contributors.

Controlled exercise and diet studies often improve liver fat, fitness, glucose or stiffness without measuring current MASH resolution. Weight-maintained exercise demonstrates that hepatic fat can improve without weight loss. The sham-controlled ESG study increases loss but has null between-group NAS/fibrosis; its achieved-loss subgroup cannot repair that assigned contrast. These results prevent a generic promise that any weight or fat improvement equals MASH or fibrosis reversal.

Drugs and surgery supply genuine additional treatment options and boundary evidence. Noncirrhotic semaglutide, tirzepatide, resmetirom and selected other trials have positive pathology outcomes, whereas compensated F4 semaglutide reduces weight/fat without positive histologic endpoints. Pioglitazone and lanifibranor can improve pathology despite weight gain, so weight loss is not universally necessary for every successful therapy. Surgery is superior to lifestyle/best medical care in BRAVES, and long-term surgery/GLP1 cohorts associate exposure with fewer hepatic events. These do not transfer their causal exposure or event evidence to lifestyle or prove weight as a necessary mediator.

## HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

### Subclaim matrix and aggregation

| Subclaim | Scope | Level | Decision |
|---|---|---|---|
| SC1 Lifestyle weight loss reduces hepatic fat. | Baseline biopsy-confirmed MASH; assigned lifestyle strategy before achieved loss | Δ | Assigned lifestyle in the Promrat paired-biopsy trial reduced steatosis relative to education, and controlled exercise/metabolic work supports direct hepatic-fat change. This is a pathological fat component crossing within its measured scope, not a substitution of fat for steatohepatitis or hard-event benefit. The disease-stage and mediator boundaries prevent high-ladder generalization. |
| SC2 Assigned lifestyle weight-loss treatment improves steatohepatitis histology. | Baseline biopsy-confirmed MASH; inflammation and ballooning rather than liver fat alone; 24-104 weeks | Δ | The newer randomized energy-restriction/HIIT trial explicitly defines histologic resolution by inflammation 0–1 and ballooning 0, and reports improvements in these components and steatohepatitis relative to its control trajectory at about ten months. This supplies a first direct assigned clinical phenotype perturbation. Its Results report resolution in 9 treatment and 0 control participants (final sample 16 and 8); the eight treated participants who reduced ballooning to 0 are compatible with nine resolutions because entry required NAS of at least 4, not ballooning of at least 1. Its small final sample, within-arm component reporting without a printed between-group test, and higher baseline MRS liver fat in controls (24% versus 15%) constrain confidence. Promrat improves a composite NAS and steatosis but has nonsignificant assigned component differences, so it reinforces activity change without being counted as a second current-resolution confirmation. The other randomized standard-care-controlled paired-biopsy lifestyle trial found on targeted search (Eckard 2013) showed improvement in every arm without a between-arm difference, so the assigned-package effect is not yet consistently reproduced. Broader clinical contexts and isolated weight mediation remain unestablished. |
| SC3 Lifestyle weight-loss treatment reverses established fibrosis. | Baseline fibrosis stage specified; assigned treatment and paired biopsy | Γ | Fibrosis is biologically and clinically modifiable by some interventions, and lifestyle cohorts associate substantial achieved loss with regression. However, both examined lifestyle-trial bodies report no significant average fibrosis change. Nonrandom achieved-loss strata and selected individual improvements cannot replace a positive controlled assigned-fibrosis result. Surgery and drug fibrosis positives demonstrate those exposures rather than lifestyle reversal. |
| SC4 Biomarker or liver-fat reduction establishes prevention of cirrhosis and liver death. | Hard clinical follow-up; no surrogate substitution | Γ | Liver-fat, ALT or histologic biomarker improvement does not itself establish prevention of cirrhosis or liver death. Bariatric and GLP1 event cohorts are separate observational exposure evidence. The small cirrhosis drug body shows fat and weight reductions alongside null histology and no observed decompensation; absence of events in a short small trial is not prevention proof. The proxy-to-hard-clinical inference remains capped. |

Preregistered aggregation: primary-subclaim. The registered primary SC2 reaches Δ with Moderate confidence: a small randomized lifestyle package changes explicit steatohepatitis histology, while the older trial offers broader activity support. Direct original-body examination prevents calling fat-only NAS changes full resolution. Evidence does not yet map sufficiently broad baseline contexts or isolate achieved weight as the causal mediator to reach Ε or mechanistically narrowed convergence. Separate Γ fibrosis and surrogate-to-event companions do not erase the positive registered clinical phenotype. Sensitivities: weakest-link Γ; primary-subclaim Δ; scope-matched Δ.

### Decisive-perturbation inventory and causal tally

[1] A 31-person randomized 48-week lifestyle-versus-education trial improved weight, NAS and steatosis; assigned inflammation/ballooning differences were nonsignificant and fibrosis unchanged. Actual Methods/Results use a composite NAS endpoint, not current resolution criteria; positive achieved-loss component strata are nonrandomized and cannot prove isolated weight mediation.

[2] Prospective 293-person lifestyle cohort with 261 paired biopsies found steatohepatitis resolution and fibrosis regression associated with greater achieved weight loss. Achieved at-least-10% subgroup is not a randomized treatment or baseline scope; no control and missing biopsies limit causal attribution and independence.

[6] Exercise at maintained weight reduced hepatic triglyceride and visceral fat in 24 biopsy-confirmed NASH adults over 12 weeks, with inflammation/fibrosis markers unchanged. No repeated biopsy and below registered 24-week gate; liver-fat improvement cannot establish steatohepatitis or fibrosis reversal.

[17] ESG versus sham with matched lifestyle in 40 biopsy-MASH adults increased loss and reduced steatosis/stiffness at 72 weeks. Between-group NAS and fibrosis were null; achieved-over-10% NAS subgroup is nonrandomized and does not rescue broad histology/fibrosis claims.

[23] ESSENCE randomized semaglutide 2.4 mg weekly in biopsy-MASH; the first 800 at 72 weeks had greater histologic resolution and fibrosis improvement than placebo. Distinct drug exposure and interim histology do not establish lifestyle mediation or the ongoing 240-week clinical-event result; pain endpoint was null and GI events more common.

[24] In 71 compensated F4 patients, 48-week semaglutide reduced weight and MRI fat but did not significantly improve biopsy fibrosis, NASH resolution or component scores. Selected original Methods/Results confirm stage-specific dissociation; absence of decompensation in this small short trial is not prevention proof and biopsy availability differed by arm.

[27] SPLENDOR associated bariatric surgery with lower long-term major adverse liver and cardiovascular events in biopsy-fibrotic NASH. Weighted observational surgery comparison is not randomized lifestyle-event evidence; raw and adjusted risk differences are different estimands, and perioperative deaths remain relevant.

[29] BRAVES randomized 288 participants and found more one-year NASH resolution with either bariatric operation than lifestyle plus best medical care. The lifestyle-arm response rate lacks an untreated comparator; surgery and cointerventions differ, and operative serious adverse events cannot be omitted.

[35] NATIVE found positive activity and selected resolution/fibrosis endpoints with high-dose lanifibranor over 24 weeks despite weight gain. Lower-dose primary significance differed; the result challenges weight-loss necessity for every therapy without refuting lifestyle sufficiency.

[39] Pioglitazone versus placebo on matched hypocaloric diet improved NASH histology in 101 prediabetic/diabetic adults over 18 months despite weight gain. The randomized addition is pioglitazone, not diet; weight gain counters universal weight-loss necessity without erasing lifestyle efficacy.

[44] A 165-person six-month LCHF versus HCLF diabetes trial improved weight and glycemia more with LCHF but found no between-group liver-biopsy NAFLD difference. Not restricted to baseline MASH and no intentional weight-loss assignment; metabolic or weight improvement is not automatic histologic reversal, and benefits waned after diet discontinuation.

[46] A small randomized ten-month energy-restriction/HIIT trial reported treatment improvements in inflammation, ballooning and steatohepatitis, while mean fibrosis remained unchanged. Actual Methods/Results define clinical histologic resolution; Results report 9 treatment and 0 control resolutions (final sample 16 and 8), reconcilable with eight treated ballooning-to-0 reductions because entry required NAS of at least 4 rather than ballooning of at least 1; component changes are reported within arm without a printed between-group test, controls entered with higher MRS liver fat (24% versus 15%), and bundled treatment and correlational mediators preclude isolated weight causality.

[61] Eckard et al. 2013 randomized 56 adults with biopsy-proven NAFLD (88% of completers with NASH) to standard care or one of three diet/exercise arms for six months with repeat biopsy. NAS improved in the 41 completers as a whole (p < 0.001) with no difference between arms, standard care included (p = 0.31). A randomized lifestyle-versus-standard-care paired-biopsy contrast was therefore null; mixed NAFLD/NASH entry, completer analysis and small arms limit it, and it does not refute the positive SC2 trial.

Tally: 2 positive qualifying study units across scoped subclaims ([1] for SC1 biopsy steatosis; [46] for SC2 inflammation/ballooning resolution); 34 screened discriminating contrast units (including the randomized null of [61]). These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. One exact current-component primary clinical positive unit; older NAS trial is complementary activity evidence, not a second current-resolution study. The Vilar prediction/renal follow-ups, LEAN/SYNERGY/MAESTRO secondary reports and semaglutide AI reassessment do not add parent units. Positive drug/surgery endpoints, imaging thresholds and achieved-loss responder analyses do not count as assigned lifestyle mediator crossings.

### Cap audit, precedence and Β/Γ/Δ boundary

A true clinical human pathology perturbation crosses Δ for its assigned lifestyle scope under the stated clinical adaptation. Universal biomarker cap 4 blocks MRI/ALT-to-histology and histology-to-hard-event inference, not the measured pathology response itself. Universal association cap 2 binds achieved-loss cohorts as isolated causal evidence, but is not re-applied to erase randomized package evidence. Different drug/surgery successes retain their own exposure and cannot be combined as independent lifestyle mediator proof.

Universal six-cap audit: Six universal caps audited: no in-vitro-only result substitutes for human pathology; achieved-loss and event cohort association remains bounded by cap 2; ectopic and forced-model sufficiency do not establish endogenous human necessity; cap 4 blocks proxy-to-clinical and activity-to-event promotion; no forced-transfer claim is made; full biological necessity/sufficiency is not claimed. No weakest evidence class is re-capped over the actual scoped randomized package result.

Gamma hard-rule audit: ROS, NAD, mitochondrial and senescence-marker-only rules were considered and do not characterize the scoped histology trial. Biomarker-only and single-model support constrain proxy and mouse inferences. The literal aging-oriented single-species rule is not silently imposed over a clinical human treatment phenotype; this clinical adaptation is declared, and no animal result is promoted to a human clinical crossing.

SC3 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Fibrosis is biologically and clinically modifiable by some interventions, and lifestyle cohorts associate substantial achieved loss with regression. However, both examined lifestyle-trial bodies report no significant average fibrosis change. Nonrandom achieved-loss strata and selected individual improvements cannot replace a positive controlled assigned-fibrosis result. Surgery and drug fibrosis positives demonstrate those exposures rather than lifestyle reversal.

SC4 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Liver-fat, ALT or histologic biomarker improvement does not itself establish prevention of cirrhosis or liver death. Bariatric and GLP1 event cohorts are separate observational exposure evidence. The small cirrhosis drug body shows fat and weight reductions alongside null histology and no observed decompensation; absence of events in a short small trial is not prevention proof. The proxy-to-hard-clinical inference remains capped.

The four field-valid definitions below quote the literal rubric 06 (aging) text; its lifespan/healthspan and developmental-versus-aging wording does not apply literally to this clinical liver claim, and each positive full-scope result is judged under the declared clinical adaptation stated in Rubric fit and in the applied rubric adaptations below.

SC1 field-valid definition: “
- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension
- Must separate developmental effects from true aging effects
- Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Assigned lifestyle in the Promrat paired-biopsy trial reduced steatosis relative to education, and controlled exercise/metabolic work supports direct hepatic-fat change. This is a pathological fat component crossing within its measured scope, not a substitution of fat for steatohepatitis or hard-event benefit. The disease-stage and mediator boundaries prevent high-ladder generalization.

SC2 field-valid definition: “
- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension
- Must separate developmental effects from true aging effects
- Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. The newer randomized energy-restriction/HIIT trial explicitly defines histologic resolution by inflammation 0–1 and ballooning 0, and reports improvements in these components and steatohepatitis relative to its control trajectory at about ten months. This supplies a first direct assigned clinical phenotype perturbation. Its Results report resolution in 9 treatment and 0 control participants (final sample 16 and 8); the eight treated participants who reduced ballooning to 0 are compatible with nine resolutions because entry required NAS of at least 4, not ballooning of at least 1. Its small final sample, within-arm component reporting without a printed between-group test, and higher baseline MRS liver fat in controls (24% versus 15%) constrain confidence. Promrat improves a composite NAS and steatosis but has nonsignificant assigned component differences, so it reinforces activity change without being counted as a second current-resolution confirmation. The other randomized standard-care-controlled paired-biopsy lifestyle trial found on targeted search (Eckard 2013) showed improvement in every arm without a between-arm difference, so the assigned-package effect is not yet consistently reproduced. Broader clinical contexts and isolated weight mediation remain unestablished.

SC3 field-valid definition: “
- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension
- Must separate developmental effects from true aging effects
- Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Fibrosis is biologically and clinically modifiable by some interventions, and lifestyle cohorts associate substantial achieved loss with regression. However, both examined lifestyle-trial bodies report no significant average fibrosis change. Nonrandom achieved-loss strata and selected individual improvements cannot replace a positive controlled assigned-fibrosis result. Surgery and drug fibrosis positives demonstrate those exposures rather than lifestyle reversal.

SC4 field-valid definition: “
- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension
- Must separate developmental effects from true aging effects
- Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Liver-fat, ALT or histologic biomarker improvement does not itself establish prevention of cirrhosis or liver death. Bariatric and GLP1 event cohorts are separate observational exposure evidence. The small cirrhosis drug body shows fat and weight reductions alongside null histology and no observed decompensation; absence of events in a short small trial is not prevention proof. The proxy-to-hard-clinical inference remains capped.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Biopsy steatosis is the directly proposed pathological component; its measured change can cross the first scoped phenotype threshold, while imaging or blood markers alone cannot prove active MASH or fibrosis reversal.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): Require concurrent assigned lifestyle treatment and paired actual inflammation/ballooning histology within registered baseline adult MASH and 24–104 weeks. Current-resolution criteria and NAS composites remain distinct; treatment-bundle sufficiency does not isolate kilograms as mediator.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): Require actual controlled fibrosis improvement at specified baseline stage; stiffness, collagen markers and response-selected biopsies are not that endpoint.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): Require hepatic clinical events or credible independently convergent clinical causal evidence; nonhepatic cardiovascular events and short-trial absence of events cannot replace cirrhosis/liver-death follow-up.

SC1 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

### Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Literal lifespan/healthspan wording does not apply to this clinical claim; satisfied under the declared clinical adaptation (assigned treatment changing paired biopsy pathology): yes.

SC1 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: no. Replicate fat-component effects across prospectively enrolled stages and diet/exercise contrasts; mechanistically separate weight, composition and activity without borrowing downstream outcomes.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Literal lifespan/healthspan wording does not apply to this clinical claim; satisfied under the declared clinical adaptation (assigned treatment changing paired biopsy pathology): yes.

SC2 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: no. Replicate predefined inflammation/ballooning resolution in adequately powered baseline-defined MASH cohorts and independently verify pathology, component estimates, attrition and safety. Map context before outcome and separate the weight mediator from the assigned package.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Obtain a sufficiently powered concurrent-control paired-biopsy lifestyle fibrosis result, with prespecified baseline stage, independent blinded readers and missing-biopsy estimands.

SC4 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Follow randomized or rigorously convergent assigned lifestyle exposures for adjudicated cirrhosis, decompensation and liver-related death; demonstrate and validate surrogate mediation rather than assume it.

Upper ladder: Assigned clinical treatment is available and supplies Δ. Adequate prospective context replication, a randomized or credible orthogonal weight-mediator test, and longer event evidence could move the claim upward. Drug classes, mouse THR-beta action and achieved-weight dose gradients concern different exposures or confounders; no set presently excludes shared lifestyle adherence, cointervention and small-study pathology failure modes for the exact primary. Human genetics and lifelong natural experiments were considered but no qualifying exact-exposure clinical set was examined.

Independence: No claim reaches Ζ. Separate small lifestyle studies use different packages and histology definitions; Promrat does not independently confirm the newer current-resolution component endpoint. Replicated or multiple drug/surgery successes are not multiple independent causal lines on assigned lifestyle or isolated weight. Shared trial secondary reports remain single units.

### Falsification and pitfalls

Fat and active/fibrotic disease dissociate. Multiple randomized comparator studies and actual lifestyle bodies show component nulls despite fat/weight improvement. This bounds inference without a second penalty. Additional downgrade: False.

Weight loss is not necessary for every successful MASH therapy. Lanifibranor and pioglitazone pathology improvements despite weight gain. This refutes universal necessity, which was not the registered lifestyle-sufficiency claim. Additional downgrade: False.

Composite endpoint substitution. NAS/steatosis is not automatically current inflammation/ballooning-defined MASH resolution.

Scope fitted to outcome. Achieved-loss and responder subsets do not replace the assigned baseline-defined estimand.

Therapeutic response treated as mechanism proof. Randomized package benefit does not isolate weight, exercise, diet composition or insulin sensitivity mediation.

Surrogate promoted to hard outcome. MRI fat, ALT, stiffness and even activity biopsy change do not alone prove liver-death prevention.

Replication confused with independence. Shared cohorts, secondary analyses, AI regrading and extensions remain their parent study.

Unchecked numerical reconstruction. New lifestyle Results give nine treatment resolutions and eight treated ballooning-to-0 reductions; these reconcile because entry required NAS of at least 4 rather than ballooning of at least 1, and no resolution fraction is reconstructed beyond the paper's own figures (9 of 16 against 0 of 8; 56% in the Discussion).

### Adversarial steelman: above, then below

Ε could be defended by combining the two randomized lifestyle studies and calling their baseline MASH populations a mapped constrained context. The strongest objection is that the older composite response does not confirm the newer current-resolution components, and the small newer trial reports its component changes within arm, without a printed between-group test and with higher baseline liver fat in controls; the other randomized standard-care-controlled paired-biopsy lifestyle trial (Eckard 2013) found no between-arm difference. Prospective replication of the same clinical phenotype with clear component estimates and stage boundaries is needed.

Γ could be defended from fat-only NAS changes and achieved-loss associations. That position accurately bounds the older trial and cohorts but would ignore the actual newer randomized trial with explicit inflammation/ballooning histology and a reported resolution positive. These are measured disease pathology, not solely blood/imaging markers.

Retain Δ rather than Γ because a direct assigned package changes the registered clinical pathology. Retain Δ rather than Ε because the specific clinical-resolution confirmation, adequate context map and mechanistic mediator remain incomplete; one broad NAS trial plus one small current-resolution trial are not a high-ladder convergent set. Fibrosis/event uncertainty is kept separate rather than downgrading the primary twice.

### Final score, causal direction and M/S/D

The registered primary SC2 reaches Δ with Moderate confidence: a small randomized lifestyle package changes explicit steatohepatitis histology, while the older trial offers broader activity support. Direct original-body examination prevents calling fat-only NAS changes full resolution. Evidence does not yet map sufficiently broad baseline contexts or isolate achieved weight as the causal mediator to reach Ε or mechanistically narrowed convergence. Separate Γ fibrosis and surrogate-to-event companions do not erase the positive registered clinical phenotype.

Assigned lifestyle precedes improvement in established disease, so the intervention contributes to modifying or maintaining the metabolic disease trajectory. Engaging/removing a specific weight mediator has not established initiation, necessity and rate limitation. This coarse role describes metabolic contribution rather than declaring weight loss a primary disease driver; a therapeutic response does not determine endogenous causal primacy.

Momentum: Mechanistic only. Completed contemporary lifestyle histology, incretin and liver-directed trials refine component and stage responses. ESSENCE has a registered longer 240-week clinical phase, but it is a drug trial and not a pending named lifestyle-primary result. No named pending exact lifestyle component-resolution result was verified in this bounded review.

Stability: Stable. The first positive clinical package evidence is established but small; no verified named pending exact lifestyle trial was identified. The newer trial's between-group component statistics and baseline liver-fat imbalance warrant clarification, while a proposed future study is not a named stability trigger.

Divergence: Contested. Do not manufacture a consensus or arithmetic evidence-belief gap from traffic ranking or provider wording. These dimensions do not change level or confidence.

## PROPOSED DECISIVE EXPERIMENTS

A multicentre lifestyle-versus-matched-support randomized trial enrolls baseline-biopsy MASH adults, stratifies fibrosis stage and diabetes before outcomes, and measures independently read paired inflammation/ballooning resolution at 52–104 weeks. Factorial diet/exercise and prospectively controlled energy/weight trajectories distinguish package efficacy from isolated mediator claims; retain all assigned participants and specify missing-biopsy sensitivity analyses. Extend blinded hepatic event follow-up.

Readout: Actual inflammation/ballooning histology, paired fibrosis and adverse events; MRI/ALT and weight are secondary. Long-term adjudicated decompensation/cirrhosis/liver-related death are separate endpoints. Controls: Matched support and medication stability, blinded independent pathology readers, prespecified stage/diabetes interaction tests, full-population assignment estimands, component counts reconciled and multiplicity addressed. Supporting: Replicated positive current-resolution differences with consistent blinded component estimates and baseline context interactions justify a higher clinical rung; controlled fibrosis/event positives must satisfy their separate claims. Falsifying: Fat-only changes without inflammation/ballooning benefit leave current-resolution unconfirmed in that context; full-population nulls cannot be rescued by selecting achieved-loss responders.

## KNOWLEDGE GAPS

Independent adequately powered current-resolution replication of assigned lifestyle in baseline MASH.

Baseline ballooning distribution and a printed between-group resolution test for PMID38914313.

Isolated weight versus activity, diet composition and peripheral metabolic mediation.

Prospective stage/diabetes interaction mapping and paired-biopsy missingness sensitivity.

Controlled lifestyle fibrosis improvement and durability beyond active histology response.

Hard hepatic events and harms beyond short selected cohorts; full supplements and all complete papers remain unaudited.

## REVIEWER NOTES

61 relevant original reports were actually examined with original abstract/status receipts (PMID23814606 added from its PubMed record on the 2026-11-02 adversarial pass); three papers have selected original Methods/Results reading receipts, not a complete-paper audit. The pool includes exact lifestyle trials plus clearly distinguished drug, surgery, mechanism and surrogate-boundary reports; it is not 61 lifestyle-MASH-resolution trials. PMID33152542 was excluded as an unexamined outcome-free design report. Linked corrections remain attached without inventing their detailed content. The 38914313 resolution and ballooning-to-0 counts are reconcilable (entry required NAS of at least 4, not ballooning of at least 1); its within-arm component reporting and baseline liver-fat imbalance are explicit. Observed signed-in Consensus Pro browser output was read and reconciled in nine original-source aspect comparisons; provider omission of the newer lifestyle trial and contemporary drug originals was corrected, and NAS response was not silently promoted to current resolution; no independent blinded review is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

## Consensus and original-source reconciliation

Observed Consensus calls the NAS composite activity reversal and its minimal-criteria count resolution. Actual Methods define improvement as a three-point NAS drop or NAS at most two; actual Results show assigned NAS/steatosis benefit but nonsignificant assigned inflammation/ballooning differences. This is genuine activity efficacy, not automatically a current inflammation/ballooning resolution result. [Original PMID19827166](https://pubmed.ncbi.nlm.nih.gov/19827166/).

Provider describes an apparent seven-percent loss threshold. Actual Results place the broader component positives in achieved-at-least-seven-percent strata, while the randomized component contrasts were nonsignificant. The weight threshold is nonrandomized association; it is not assigned-dose necessity, a baseline eligibility boundary or justification to exclude nonresponders. [Original PMID19827166](https://pubmed.ncbi.nlm.nih.gov/19827166/).

Provider gives 31 randomized participants and percentages but omits actual endpoint-biopsy availability. Original Results show 28 of 31 with paired biopsy: 18 of 21 lifestyle and all 10 controls. Therefore its 72-versus-30-percent composite is an available-biopsy comparison, not a silent 31-person complete-pathology audit; missingness and small power limit certainty. [Original PMID19827166](https://pubmed.ncbi.nlm.nih.gov/19827166/).

Provider identifies Promrat as the only small randomized lifestyle histology trial. The examined newer original Methods/Results contain a randomized ten-month energy-restriction/HIIT comparison with explicit inflammation/ballooning resolution and activity benefit. Provider corpus omission cannot establish absence. Original Results report 9 treatment and 0 control resolutions (final sample 16 and 8; the Discussion gives 56%) and eight treated participants reducing ballooning to 0, which reconcile because entry required NAS of at least 4 rather than ballooning of at least 1; component changes are reported within arm, with no printed between-group test and higher baseline liver fat in controls. [Original PMID38914313](https://pubmed.ncbi.nlm.nih.gov/38914313/).

Provider correctly distinguishes the nonrandomized cohort and larger achieved-loss response. The examined original abstract reports 293 enrolled and 261 paired biopsies with subgroup resolution/regression associations. The follow-up prediction PMID26849287 shares that cohort; different subgroup counts or prediction models do not constitute a new causal trial. No complete cohort body was examined. [Original PMID25865049](https://pubmed.ncbi.nlm.nih.gov/25865049/).

Provider correctly retains BRAVES surgery superiority. The original trial abstract distinguishes ITT and available-protocol response rates. Lifestyle plus best medical care is a comparator to surgery, so its response percentage cannot establish efficacy versus untreated patients or isolate lifestyle weight mediation. Surgery adverse events remain part of its separate evidence. [Original PMID37088093](https://pubmed.ncbi.nlm.nih.gov/37088093/).

Provider treats five-year surgery biopsy benefit as distinct from lifestyle and reports incomplete biopsy availability. The examined original abstract supports substantial observed resolution/regression with 64 of 94 five-year-eligible patients biopsied. It is selected uncontrolled long-term surgery, outside the registered 24–104-week lifestyle primary; absence of statistically different observed groups does not rule out unmeasured nonresponse bias. [Original PMID32553765](https://pubmed.ncbi.nlm.nih.gov/32553765/).

Provider discusses component dissociation largely through older trials and reviews, with recent originals absent from its indexed text. The selected F4 semaglutide original Methods/Results directly show significant weight/MRI-fat reduction but null biopsy resolution/fibrosis at 48 weeks, differential biopsy availability and no decompensation events. This is a stage/drug boundary; it neither proves lifestyle failure nor event prevention from biomarkers. [Original PMID36934740](https://pubmed.ncbi.nlm.nih.gov/36934740/).

Provider explicitly lacks ESSENCE, SYNERGY-NASH and MAESTRO-NASH primary details. Examined original abstracts PMID40305708,38856224,38324483 retain genuine respective clinical-pathology positives. A review search cutoff is not the present evidence cutoff, and those drug effects cannot be borrowed as lifestyle or isolated-weight causal lines. [Original PMID40305708](https://pubmed.ncbi.nlm.nih.gov/40305708/).

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

## Research timeline and gaps: Lifestyle Weight Loss and MASH Reversal

Selected publication milestones, not an exhaustive history or discovery priority claim.

**2010 — Randomized assigned lifestyle improves NAS and steatosis; current component definitions and achieved-loss strata remain distinct.** [Original PMID19827166](https://pubmed.ncbi.nlm.nih.gov/19827166/).

**2011 — A shared lifestyle-trial molecular follow-up adds ceramide leads rather than an independent clinical outcome unit.** [Original PMID21794038](https://pubmed.ncbi.nlm.nih.gov/21794038/).

**2013 — Mediterranean-diet fat improvement without different loss separates diet composition from weight mediation.** [Original PMID23485520](https://pubmed.ncbi.nlm.nih.gov/23485520/).

**2015 — Large paired-biopsy lifestyle cohort makes achieved-loss resolution and regression associations visible.** [Original PMID25865049](https://pubmed.ncbi.nlm.nih.gov/25865049/).

**2016 — LEAN supplies a distinct randomized drug histology positive with incomplete endpoint biopsies.** [Original PMID26608256](https://pubmed.ncbi.nlm.nih.gov/26608256/).

**2016 — Pioglitazone improves pathology despite weight gain, challenging universal weight-loss necessity.** [Original PMID27322798](https://pubmed.ncbi.nlm.nih.gov/27322798/).

**2017 — Weight-maintained exercise reduces hepatic fat without proving inflammation or fibrosis reversal.** [Original PMID27521509](https://pubmed.ncbi.nlm.nih.gov/27521509/).

**2018 — FLINT achieved-weight posthoc analysis illustrates additive response and nonrandom mediation limits.** [Original PMID29333665](https://pubmed.ncbi.nlm.nih.gov/29333665/).

**2019 — Obeticholic acid separates a fibrosis positive from a nonsignificant steatohepatitis-resolution outcome.** [Original PMID31813633](https://pubmed.ncbi.nlm.nih.gov/31813633/).

**2020 — Five-year bariatric biopsies reveal durable observed resolution/regression with selective follow-up.** [Original PMID32553765](https://pubmed.ncbi.nlm.nih.gov/32553765/).

**2021 — Daily semaglutide shows resolution efficacy while categorical fibrosis is nonsignificant.** [Original PMID33185364](https://pubmed.ncbi.nlm.nih.gov/33185364/).

**2021 — Lanifibranor demonstrates clinical-pathology efficacy despite weight gain and dose-specific significance.** [Original PMID34670042](https://pubmed.ncbi.nlm.nih.gov/34670042/).

**2021 — SPLENDOR contributes observational long-term surgery-event evidence rather than a surrogate-based lifestyle proof.** [Original PMID34762106](https://pubmed.ncbi.nlm.nih.gov/34762106/).

**2023 — Randomized diet metabolic/weight improvements do not guarantee a biopsy difference.** [Original PMID36508737](https://pubmed.ncbi.nlm.nih.gov/36508737/).

**2023 — Compensated cirrhosis semaglutide has weight/MRI-fat benefit without a positive histologic endpoint.** [Original PMID36934740](https://pubmed.ncbi.nlm.nih.gov/36934740/).

**2023 — BRAVES provides an actual surgery-versus-lifestyle/best-care randomized biopsy comparison.** [Original PMID37088093](https://pubmed.ncbi.nlm.nih.gov/37088093/).

**2024 — MAESTRO-NASH establishes resmetirom histology efficacy for a separate liver-directed exposure.** [Original PMID38324483](https://pubmed.ncbi.nlm.nih.gov/38324483/).

**2024 — SYNERGY-NASH adds tirzepatide pathology positives, with missing biopsies and an attached erratum.** [Original PMID38856224](https://pubmed.ncbi.nlm.nih.gov/38856224/).

**2024 — A newer small lifestyle RCT reports explicit component/resolution benefits with average fibrosis unchanged; within-arm component reporting and a baseline liver-fat imbalance limit it.** [Original PMID38914313](https://pubmed.ncbi.nlm.nih.gov/38914313/).

**2025 — ESSENCE interim 72-week semaglutide pathology positives precede its ongoing longer clinical phase.** [Original PMID40305708](https://pubmed.ncbi.nlm.nih.gov/40305708/).

**2025 — SYNERGY responder/mediation analysis generates weight-related leads without randomized mediator identity.** [Original PMID41066427](https://pubmed.ncbi.nlm.nih.gov/41066427/).

**2026 — Older-adult GLP1 cohort associates exposure with hepatic outcomes while MACE is null; observational event evidence remains separate.** [Original PMID42765724](https://pubmed.ncbi.nlm.nih.gov/42765724/).

## Research gaps

Independent adequately powered current-resolution replication of assigned lifestyle in baseline MASH.

Baseline ballooning distribution and a printed between-group resolution test for PMID38914313.

Isolated weight versus activity, diet composition and peripheral metabolic mediation.

Prospective stage/diabetes interaction mapping and paired-biopsy missingness sensitivity.

Controlled lifestyle fibrosis improvement and durability beyond active histology response.

Hard hepatic events and harms beyond short selected cohorts; full supplements and all complete papers remain unaudited.

## Boundary experiment

A multicentre lifestyle-versus-matched-support randomized trial enrolls baseline-biopsy MASH adults, stratifies fibrosis stage and diabetes before outcomes, and measures independently read paired inflammation/ballooning resolution at 52–104 weeks. Factorial diet/exercise and prospectively controlled energy/weight trajectories distinguish package efficacy from isolated mediator claims; retain all assigned participants and specify missing-biopsy sensitivity analyses. Extend blinded hepatic event follow-up.


## ADVERSARIAL REVIEW AND APPROVAL

**Authoring model:** Sol 6.1. **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-14.

**Scope of checks:** All 60 reference PMIDs re-fetched with the PubMed MCP tool get_article_metadata (title, first author, journal, year, DOI): 60/60 resolve to the stated record; no retraction or expression of concern. 12 load-bearing claims spot-checked against PubMed abstracts and, for PMIDs 19827166, 38914313 and 36934740, against the local full-text/ passages: refs 1, 2, 6, 17, 23, 24, 27, 29, 35, 39, 44, 46. Scoring logic checked against the archived HSEF v5.3 framework (hard caps first, declared primary-subclaim aggregation, Gamma hard rules, B/Gamma/Delta boundary, independence basis). Known upstream defects checked: collective-author dropping (none present), scope-matched aggregation misread (not applicable; declared rule is primary-subclaim and is applied as written), momentum boilerplate (already "Mechanistic only"; no completed study is cited as pending work), rendering defects (two found, corrected).

**Findings and corrections**

| ID | Severity | Location | Original -> corrected | Evidence |
|---|---|---|---|---|
| WM-1 | Major | AT A GLANCE, "Best-supported rival" | "Energy balance and adiposity change reverse steatohepatitis" -> "Fat, inflammation and fibrosis have distinct treatment responses (tournament rank 1; non-nominal); Delta", with a closing sentence placing the nominal model at rank 2 | scorecard competing_models.models_evaluated[0] is M1 with is_nominal true and rank_in_tournament 2; the rival is M2 (rank 1, is_nominal false). The renderer printed models_evaluated[0] regardless of those fields, so the review named its own nominal model as the rival. The paragraph's own evidence (component dissociation) already argues M2. |
| WM-2 | Major | scorecard final_score.confidence_rationale | "...3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence..." -> rationale resting on density and reproducibility: one small unreplicated current-resolution trial, its unresolved internal count discrepancy, the older trial's nonsignificant assigned component contrasts, and heterogeneous packages/comparators/histology definitions | Lead policy: reading access is not evidence density or reproducibility and cannot set a band. Re-derived under the two-step test, the band stays **Moderate** — the review documents substantive reproducibility concerns (a single n=16-treatment trial as the only current-resolution positive, 9-resolution/8-ballooning-zero discrepancy, null fibrosis), far short of the High text's "extensive independent replication across labs, models, and assay modalities". No level or confidence change. |
| WM-3 | Minor | REFERENCES [22] and scorecard citation_ledger n=22 | "DOI: ." (empty field) -> "DOI: not indexed in PubMed."; ledger doi "" -> null with doi_note | PubMed record for PMID 26367736 carries no DOI element; the empty rendered field is the known builder defect. |
| WM-4 | Editorial | Evidence card [22] "Shows" | "Silymarin/vitaminE-plus-diet" -> "Silymarin/vitamin-E-plus-diet" | Glued-word rendering defect. |
| WM-5 | Editorial | Causal tally line | "1 positive qualifying study units" -> "1 positive qualifying study unit" | Number agreement; scorecard causal_tally_audit.tally_after_audit is 1. |

**Rejected findings (checked, no change)**

- Delta rather than Gamma for SC2: PMID 38914313's Methods define resolution as post-treatment inflammation 0-1 and ballooning 0, and its Results report resolution in 9 treatment and 0 control subjects with reductions in inflammation, ballooning and steatohepatitis activity. That is a measured disease-pathology perturbation under an assigned randomized package, not a biomarker-only change, so no universal cap or Gamma hard rule forces Gamma. Verified in the local full text.
- The flagged 9-resolution/8-ballooning-zero inconsistency is real and correctly characterised: the Results state "Resolution of steatohepatitis was achieved in 9 treatment subjects" and, for components, "8 reduced hepatocellular ballooning to a 0". Declining to publish a derived resolution fraction is a defensible judgement call.
- Promrat (PMID 19827166) attribution: the local full text confirms "The change in parenchymal inflammation, ballooning injury and fibrosis scores did not differ significantly between the two groups" and 11/18 versus 2/10 paired-biopsy responders, i.e. 28 of 31 randomized with paired biopsy (18 of 21 lifestyle, 10 of 10 control). The review's wording matches.
- ESSENCE (PMID 40305708) card: 1197 randomized, interim week-72 analysis of the first 800, 62.9% versus 34.3% resolution, 36.8% versus 22.4% fibrosis reduction, bodily-pain scores not significantly different, more gastrointestinal adverse events - all match the abstract. The 240-week phase is correctly described as ongoing and as drug rather than lifestyle evidence.
- Compensated-cirrhosis semaglutide (PMID 36934740): 71 enrolled, 48 weeks, no significant fibrosis improvement (11% versus 29%, p=0.087) and no significant NASH resolution difference - matches the abstract; the review does not overstate the null as evidence of harm or of lifestyle failure.
- Print/e-pub year differences at refs 4, 6, 13, 17, 34 and others (+/-1): acceptable under the stated convention.
- Momentum "Mechanistic only" with ESSENCE named: the artifact explicitly declines to treat a completed drug interim or the registered 240-week drug phase as pending lifestyle-primary work. Correct under the lead's momentum policy; no change.
- "v5.claim_form" phenomenon-style wording: the registered claim states an intervention plus a histological consequence, so the convention is to reject this warning.

**Residual limitations**

- 57 of 60 sources were verified at abstract/status depth; partial-body verification covers the three receipted papers (PMIDs 19827166, 38914313, 36934740). This bounds what was checked; per lead policy it is not a determinant of the confidence band.
- scorecard provenance_header.generated_by reads "Codex; HSEF v5.3" and review_metadata.reviewer reads "Codex". Authorship is recorded here as Sol 6.1 per the mandate; the fields were not altered.
- Batch-level files (OVERVIEW/README, READER.html, BATCH_COMPLETION.json, SHA256.txt) were not edited; propagation strings are listed in the agent report.

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

## ADVERSARIAL REVIEW AND APPROVAL: SECOND PASS (2026-11-02)

**Authoring model:** Sol 6.1 (score card `provenance_header.generated_by` reads "Codex; HSEF v5.3"; unresolved and carried forward). **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-11-02.

**Scope of checks:** All 60 REFERENCES PMIDs re-fetched with PubMed get_article_metadata (60/60 resolve; no retraction or expression of concern). 23 load-bearing claims spot-checked, with PMC full text for PMIDs 19827166 and 38914313. Scoring re-derived from the review's own inventory. A targeted PubMed search for randomized paired-biopsy lifestyle trials identified PMID 23814606, verified in PubMed before it was added. The full log is [ADVERSARIAL_REVIEW.weight-loss-mash-reversal.md](ADVERSARIAL_REVIEW.weight-loss-mash-reversal.md) with machine-readable findings in [adversarial-findings.weight-loss-mash-reversal.json](adversarial-findings.weight-loss-mash-reversal.json).

**Corrections applied**

| ID | Severity | Correction |
|---|---|---|
| WL-1 | Major | The PMID38914313 nine-resolution/eight-ballooning-to-0 counts are reconcilable (entry required NAS of at least 4, not ballooning of at least 1); the supposed inconsistency was removed from the evidence text, SC2 rationale, inventory/card [46], pitfalls, steelman, Stability, gaps, reviewer notes, Consensus reconciliation, timeline and confidence rationale, and replaced with the real caveats (within-arm component reporting, no printed between-group test, higher baseline liver fat in controls). This overturns the 2026-10-14 rejected finding that called the inconsistency real. |
| WL-2 | Major | Eckard 2013 (PMID 23814606; randomized, standard-care-controlled, paired-biopsy; no between-arm difference) added to the SC2 rationale, the decisive-perturbation inventory as [61], the M1 tournament entry, REFERENCES 61, a new evidence card and the score card ledger/inventory/claims. Screened discriminating contrasts 33 to 34. |
| WL-3 | Minor | Tally 1 to 2 positive qualifying study units ([1] for SC1; [46] for SC2). |
| WL-4 | Minor | Rank-5 null rival added: non-specific trial effects, regression to the mean and biopsy sampling variability (Γ). |
| WL-5 | Minor | SC1/SC2 Δ ladder lines state that the literal lifespan/healthspan wording does not apply and that the crossing is under the declared clinical adaptation; one-line preface added before the four literal rubric 06 field-valid quotes. |
| WL-6 | Minor | Reader-summary limitation no longer attributes confidence to reading access. |
| WL-7 | Minor | "ErratumIn" spacing restored to "Erratum In" on cards [33], [38], [50] and in the score card status flags. |
| WL-8 | Editorial | Doubled full stops removed in PROPOSED DECISIVE EXPERIMENTS. |

**Level and confidence:** Δ and Moderate, unchanged. SC2 still clears Δ on 9 of 16 against 0 of 8 resolutions; Moderate rests on a single small unreplicated current-resolution trial with baseline imbalance and the randomized null of Eckard 2013, not on reading access.

**Approval:** Following the second adversarial review and the corrections listed above, the revised document is approved. - Claude Opus 5.5 (Anthropic), 2026-11-02.

## REFERENCES

1. Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.). 2010. [PMID 19827166](https://pubmed.ncbi.nlm.nih.gov/19827166/). DOI: 10.1002/hep.23276. Access: full_text_partial. Study: PROMRAT-LIFESTYLE.

2. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015. [PMID 25865049](https://pubmed.ncbi.nlm.nih.gov/25865049/). DOI: 10.1053/j.gastro.2015.04.005. Access: abstract_metadata. Study: VILAR-LIFESTYLE-293.

3. Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology (Baltimore, Md.). 2016. [PMID 26849287](https://pubmed.ncbi.nlm.nih.gov/26849287/). DOI: 10.1002/hep.28484. Access: abstract_metadata. Study: VILAR-LIFESTYLE-293.

4. Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL et al. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2017. [PMID 27862096](https://pubmed.ncbi.nlm.nih.gov/27862096/). DOI: 10.1111/apt.13860. Access: abstract_metadata. Study: VILAR-LIFESTYLE-293.

5. Promrat K, Longato L, Wands JR et al. Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatology research : the official journal of the Japan Society of Hepatology. 2011. [PMID 21794038](https://pubmed.ncbi.nlm.nih.gov/21794038/). DOI: 10.1111/j.1872-034X.2011.00815.x. Access: abstract_metadata. Study: PROMRAT-LIFESTYLE.

6. Houghton D, Thoma C, Hallsworth K et al. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017. [PMID 27521509](https://pubmed.ncbi.nlm.nih.gov/27521509/). DOI: 10.1016/j.cgh.2016.07.031. Access: abstract_metadata. Study: PMID27521509.

7. Cuthbertson DJ, Keating SE, Pugh CJA et al. Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease. Liver international : official journal of the International Association for the Study of the Liver. 2024. [PMID 38847589](https://pubmed.ncbi.nlm.nih.gov/38847589/). DOI: 10.1111/liv.15947. Access: abstract_metadata. Study: PMID38847589.

8. Hallsworth K, Thoma C, Hollingsworth KG et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clinical science (London, England : 1979). 2015. [PMID 26265792](https://pubmed.ncbi.nlm.nih.gov/26265792/). DOI: 10.1042/CS20150308. Access: abstract_metadata. Study: PMID26265792.

9. Katsagoni CN, Papatheodoridis GV, Ioannidou P et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. The British journal of nutrition. 2018. [PMID 29947322](https://pubmed.ncbi.nlm.nih.gov/29947322/). DOI: 10.1017/S000711451800137X. Access: abstract_metadata. Study: PMID29947322.

10. Ezpeleta M, Gabel K, Cienfuegos S et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell metabolism. 2023. [PMID 36549296](https://pubmed.ncbi.nlm.nih.gov/36549296/). DOI: 10.1016/j.cmet.2022.12.001. Access: abstract_metadata. Study: PMID36549296.

11. Dallio M, Romeo M, Di Nardo F et al. A multidisciplinary nutritional-behavioral intervention improves weight loss and liver-related outcomes in patients with metabolic dysfunction-associated steatotic liver disease: A randomized controlled trial. Clinical nutrition (Edinburgh, Scotland). 2026. [PMID 42805146](https://pubmed.ncbi.nlm.nih.gov/42805146/). DOI: 10.1016/j.clnu.2026.106800. Access: abstract_metadata. Study: PMID42805146.

12. Wu Y, Li L, Zhang X et al. Isocaloric-restricted traditional Jiangnan diet combined with physical exercise on non-alcoholic fatty liver disease: a randomized controlled trial. Nutrition & metabolism. 2026. [PMID 41933392](https://pubmed.ncbi.nlm.nih.gov/41933392/). DOI: 10.1186/s12986-026-01105-4. Access: abstract_metadata. Study: PMID41933392.

13. Scaglioni F, Marino M, Ciccia S et al. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clinics and research in hepatology and gastroenterology. 2013. [PMID 23273500](https://pubmed.ncbi.nlm.nih.gov/23273500/). DOI: 10.1016/j.clinre.2012.10.009. Access: abstract_metadata. Study: PMID23273500.

14. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Alimentary pharmacology & therapeutics. 2009. [PMID 19691668](https://pubmed.ncbi.nlm.nih.gov/19691668/). DOI: 10.1111/j.1365-2036.2009.04122.x. Access: abstract_metadata. Study: PMID19691668.

15. Harrison SA, Fincke C, Helinski D et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Alimentary pharmacology & therapeutics. 2004. [PMID 15352910](https://pubmed.ncbi.nlm.nih.gov/15352910/). DOI: 10.1111/j.1365-2036.2004.02153.x. Access: abstract_metadata. Study: PMID15352910.

16. Lee YM, Low HC, Lim LG et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointestinal endoscopy. 2012. [PMID 22840293](https://pubmed.ncbi.nlm.nih.gov/22840293/). DOI: 10.1016/j.gie.2012.05.023. Access: abstract_metadata. Study: PMID22840293.

17. Abad J, Llop E, Arias-Loste MT et al. Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2025. [PMID 39694202](https://pubmed.ncbi.nlm.nih.gov/39694202/). DOI: 10.1016/j.cgh.2024.10.027. Access: abstract_metadata. Study: PMID39694202.

18. Noureddin M, Rinella M, Taub R et al. Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Alimentary pharmacology & therapeutics. 2025. [PMID 41127972](https://pubmed.ncbi.nlm.nih.gov/41127972/). DOI: 10.1111/apt.70382. Access: abstract_metadata. Study: MAESTRO-NASH.

19. Bomhof MR, Parnell JA, Ramay HR et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. European journal of nutrition. 2019. [PMID 29779170](https://pubmed.ncbi.nlm.nih.gov/29779170/). DOI: 10.1007/s00394-018-1721-2. Access: abstract_metadata. Study: PMID29779170.

20. Wong VW, Neff GW, Di Bisceglie AM et al. HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clinical and molecular hepatology. 2025. [PMID 40258699](https://pubmed.ncbi.nlm.nih.gov/40258699/). DOI: 10.3350/cmh.2025.0145. Access: abstract_metadata. Study: PMID40258699.

21. Saadati S, Hatami B, Yari Z et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. European journal of clinical nutrition. 2019. [PMID 30610213](https://pubmed.ncbi.nlm.nih.gov/30610213/). DOI: 10.1038/s41430-018-0382-9. Access: abstract_metadata. Study: PMID30610213.

22. Aller R, Izaola O, Gómez S et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. European review for medical and pharmacological sciences. 2015. [PMID 26367736](https://pubmed.ncbi.nlm.nih.gov/26367736/). DOI: not indexed in PubMed. Access: abstract_metadata. Study: PMID26367736.

23. Sanyal AJ, Newsome PN, Kliers I et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. The New England journal of medicine. 2025. [PMID 40305708](https://pubmed.ncbi.nlm.nih.gov/40305708/). DOI: 10.1056/NEJMoa2413258. Access: abstract_metadata. Study: PMID40305708.

24. Loomba R, Abdelmalek MF, Armstrong MJ et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The lancet. Gastroenterology & hepatology. 2023. [PMID 36934740](https://pubmed.ncbi.nlm.nih.gov/36934740/). DOI: 10.1016/S2468-1253(23)00068-7. Access: full_text_partial. Study: PMID36934740.

25. Newsome PN, Buchholtz K, Cusi K et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. The New England journal of medicine. 2021. [PMID 33185364](https://pubmed.ncbi.nlm.nih.gov/33185364/). DOI: 10.1056/NEJMoa2028395. Access: abstract_metadata. Study: SEMA-DAILY-NCT02970942.

26. Lassailly G, Caiazzo R, Ntandja-Wandji LC et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020. [PMID 32553765](https://pubmed.ncbi.nlm.nih.gov/32553765/). DOI: 10.1053/j.gastro.2020.06.006. Access: abstract_metadata. Study: PMID32553765.

27. Aminian A, Al-Kurd A, Wilson R et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA. 2021. [PMID 34762106](https://pubmed.ncbi.nlm.nih.gov/34762106/). DOI: 10.1001/jama.2021.19569. Access: abstract_metadata. Study: PMID34762106.

28. Flint A, Andersen G, Hockings P et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Alimentary pharmacology & therapeutics. 2021. [PMID 34570916](https://pubmed.ncbi.nlm.nih.gov/34570916/). DOI: 10.1111/apt.16608. Access: abstract_metadata. Study: PMID34570916.

29. Verrastro O, Panunzi S, Castagneto-Gissey L et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet (London, England). 2023. [PMID 37088093](https://pubmed.ncbi.nlm.nih.gov/37088093/). DOI: 10.1016/S0140-6736(23)00634-7. Access: abstract_metadata. Study: PMID37088093.

30. Alkhouri N, Herring R, Kabler H et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of hepatology. 2022. [PMID 35439567](https://pubmed.ncbi.nlm.nih.gov/35439567/). DOI: 10.1016/j.jhep.2022.04.003. Access: abstract_metadata. Study: PMID35439567.

31. Ratziu V, Francque S, Behling CA et al. Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.). 2024. [PMID 38112484](https://pubmed.ncbi.nlm.nih.gov/38112484/). DOI: 10.1097/HEP.0000000000000723. Access: abstract_metadata. Study: SEMA-DAILY-NCT02970942.

32. Harrison SA, Bedossa P, Guy CD et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. The New England journal of medicine. 2024. [PMID 38324483](https://pubmed.ncbi.nlm.nih.gov/38324483/). DOI: 10.1056/NEJMoa2309000. Access: abstract_metadata. Study: MAESTRO-NASH.

33. Loomba R, Hartman ML, Lawitz EJ et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England journal of medicine. 2024. [PMID 38856224](https://pubmed.ncbi.nlm.nih.gov/38856224/). DOI: 10.1056/NEJMoa2401943. Access: abstract_metadata. Study: SYNERGY-NASH.

34. Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England). 2016. [PMID 26608256](https://pubmed.ncbi.nlm.nih.gov/26608256/). DOI: 10.1016/S0140-6736(15)00803-X. Access: abstract_metadata. Study: LEAN.

35. Francque SM, Bedossa P, Ratziu V et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. The New England journal of medicine. 2021. [PMID 34670042](https://pubmed.ncbi.nlm.nih.gov/34670042/). DOI: 10.1056/NEJMoa2036205. Access: abstract_metadata. Study: PMID34670042.

36. Harrison SA, Bashir MR, Guy CD et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England). 2019. [PMID 31727409](https://pubmed.ncbi.nlm.nih.gov/31727409/). DOI: 10.1016/S0140-6736(19)32517-6. Access: abstract_metadata. Study: RESMET-PHASE2.

37. Song Y, Ni W, Zheng M et al. Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study. Cell reports. Medicine. 2025. [PMID 39970876](https://pubmed.ncbi.nlm.nih.gov/39970876/). DOI: 10.1016/j.xcrm.2025.101939. Access: abstract_metadata. Study: PMID39970876.

38. Younossi ZM, Ratziu V, Loomba R et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2019. [PMID 31813633](https://pubmed.ncbi.nlm.nih.gov/31813633/). DOI: 10.1016/S0140-6736(19)33041-7. Access: abstract_metadata. Study: REGENERATE.

39. Cusi K, Orsak B, Bril F et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Annals of internal medicine. 2016. [PMID 27322798](https://pubmed.ncbi.nlm.nih.gov/27322798/). DOI: 10.7326/M15-1774. Access: abstract_metadata. Study: PMID27322798.

40. Henney AE, Riley DR, Anson M et al. Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Liver international : official journal of the International Association for the Study of the Liver. 2025. [PMID 40980971](https://pubmed.ncbi.nlm.nih.gov/40980971/). DOI: 10.1111/liv.70367. Access: abstract_metadata. Study: PMID40980971.

41. Caussy C, Cusi K, Rosenstock J et al. Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide. Diabetes care. 2025. [PMID 41066427](https://pubmed.ncbi.nlm.nih.gov/41066427/). DOI: 10.2337/dc25-1306. Access: abstract_metadata. Study: SYNERGY-NASH.

42. Mironova M, Padmanabhan K, Schneider D et al. Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset. Alimentary pharmacology & therapeutics. 2026. [PMID 42527732](https://pubmed.ncbi.nlm.nih.gov/42527732/). DOI: 10.1111/apt.70888. Access: abstract_metadata. Study: MAESTRO-NASH.

43. Hameed B, Terrault NA, Gill RM et al. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2018. [PMID 29333665](https://pubmed.ncbi.nlm.nih.gov/29333665/). DOI: 10.1111/apt.14492. Access: abstract_metadata. Study: FLINT-NCT01265498.

44. Hansen CD, Gram-Kampmann EM, Hansen JK et al. Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial. Annals of internal medicine. 2023. [PMID 36508737](https://pubmed.ncbi.nlm.nih.gov/36508737/). DOI: 10.7326/M22-1787. Access: abstract_metadata. Study: PMID36508737.

45. Ryan MC, Itsiopoulos C, Thodis T et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of hepatology. 2013. [PMID 23485520](https://pubmed.ncbi.nlm.nih.gov/23485520/). DOI: 10.1016/j.jhep.2013.02.012. Access: abstract_metadata. Study: PMID23485520.

46. Mucinski JM, Salvador AF, Moore MP et al. Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH. Journal of hepatology. 2024. [PMID 38914313](https://pubmed.ncbi.nlm.nih.gov/38914313/). DOI: 10.1016/j.jhep.2024.06.017. Access: full_text_partial. Study: NCT03151798.

47. Cheng R, Wang L, Le S et al. A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease. Nature communications. 2022. [PMID 35538056](https://pubmed.ncbi.nlm.nih.gov/35538056/). DOI: 10.1038/s41467-022-29968-0. Access: abstract_metadata. Study: PMID35538056.

48. Chooi YC, Zhang QA, Magkos F et al. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. The American journal of clinical nutrition. 2024. [PMID 38035997](https://pubmed.ncbi.nlm.nih.gov/38035997/). DOI: 10.1016/j.ajcnut.2023.11.013. Access: abstract_metadata. Study: PMID38035997.

49. Cunha GM, Guzman G, Correa De Mello LL et al. Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity. Frontiers in endocrinology. 2020. [PMID 33042004](https://pubmed.ncbi.nlm.nih.gov/33042004/). DOI: 10.3389/fendo.2020.00607. Access: abstract_metadata. Study: PMID33042004.

50. Schwimmer JB, Ugalde-Nicalo P, Welsh JA et al. Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial. JAMA. 2019. [PMID 30667502](https://pubmed.ncbi.nlm.nih.gov/30667502/). DOI: 10.1001/jama.2018.20579. Access: abstract_metadata. Study: PMID30667502.

51. Armstrong MJ, Hull D, Guo K et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of hepatology. 2016. [PMID 26394161](https://pubmed.ncbi.nlm.nih.gov/26394161/). DOI: 10.1016/j.jhep.2015.08.038. Access: abstract_metadata. Study: LEAN.

52. Takahashi H, Kessoku T, Kawanaka M et al. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatology communications. 2022. [PMID 34558835](https://pubmed.ncbi.nlm.nih.gov/34558835/). DOI: 10.1002/hep4.1696. Access: abstract_metadata. Study: PMID34558835.

53. Younossi ZM, Stepanova M, Racila A et al. Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology (Baltimore, Md.). 2025. [PMID 39250515](https://pubmed.ncbi.nlm.nih.gov/39250515/). DOI: 10.1097/HEP.0000000000001084. Access: abstract_metadata. Study: MAESTRO-NASH.

54. Harrison SA, Bashir M, Moussa SE et al. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Hepatology communications. 2021. [PMID 33860116](https://pubmed.ncbi.nlm.nih.gov/33860116/). DOI: 10.1002/hep4.1657. Access: abstract_metadata. Study: RESMET-PHASE2.

55. Koutouratsas T, Kalligeros M, Michael M et al. GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study. Age and ageing. 2026. [PMID 42765724](https://pubmed.ncbi.nlm.nih.gov/42765724/). DOI: 10.1093/ageing/afag281. Access: abstract_metadata. Study: PMID42765724.

56. Browne SK, Suschak JJ, Tomah S et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP reports : innovation in hepatology. 2025. [PMID 41113119](https://pubmed.ncbi.nlm.nih.gov/41113119/). DOI: 10.1016/j.jhepr.2025.101483. Access: abstract_metadata. Study: PMID41113119.

57. Harrison SA, Taub R, Neff GW et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine. 2023. [PMID 37845512](https://pubmed.ncbi.nlm.nih.gov/37845512/). DOI: 10.1038/s41591-023-02603-1. Access: abstract_metadata. Study: MAESTRO-NAFLD1.

58. Barb D, Kalavalapalli S, Godinez Leiva E et al. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. Journal of hepatology. 2025. [PMID 39824443](https://pubmed.ncbi.nlm.nih.gov/39824443/). DOI: 10.1016/j.jhep.2024.12.045. Access: abstract_metadata. Study: PMID39824443.

59. Kannt A, Wohlfart P, Madsen AN et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. British journal of pharmacology. 2021. [PMID 33655500](https://pubmed.ncbi.nlm.nih.gov/33655500/). DOI: 10.1111/bph.15427. Access: abstract_metadata. Study: PMID33655500.

60. Stine JG, Xu D, Schmitz K et al. Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease. Digestive diseases and sciences. 2020. [PMID 32239376](https://pubmed.ncbi.nlm.nih.gov/32239376/). DOI: 10.1007/s10620-020-06226-1. Access: abstract_metadata. Study: PMID32239376.

61. Eckard C, Cole R, Lockwood J et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therapeutic advances in gastroenterology. 2013. [PMID 23814606](https://pubmed.ncbi.nlm.nih.gov/23814606/). DOI: 10.1177/1756283X13484078. Access: abstract_metadata. Study: PMID23814606.

## Source-specific evidence cards

### [1] Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.

**Shows:** A 31-person randomized 48-week lifestyle-versus-education trial improved weight, NAS and steatosis; assigned inflammation/ballooning differences were nonsignificant and fibrosis unchanged.

**Does not show:** Actual Methods/Results use a composite NAS endpoint, not current resolution criteria; positive achieved-loss component strata are nonrandomized and cannot prove isolated weight mediation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph0, 0:Methods:paragraph1, 0:Methods:paragraph2, 0:Methods:paragraph11, 0:Methods:paragraph13, 0:Methods:paragraph14, 1:Results:paragraph0, 1:Results:paragraph1, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph8, 1:Results:paragraph9, 1:Results:paragraph12. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [2] Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

**Shows:** Prospective 293-person lifestyle cohort with 261 paired biopsies found steatohepatitis resolution and fibrosis regression associated with greater achieved weight loss.

**Does not show:** Achieved at-least-10% subgroup is not a randomized treatment or baseline scope; no control and missing biopsies limit causal attribution and independence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [3] Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.

**Shows:** A split development/validation analysis predicts histologic resolution using weight loss, metabolic status, ALT and baseline features.

**Does not show:** Shares the lifestyle cohort; posttreatment predictors and internal validation are not a new causal trial or proof of prevented clinical events.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

### [4] Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.

**Shows:** Shared lifestyle-cohort posthoc analysis associates histology improvement with eGFR change over 52 weeks.

**Does not show:** Renal correlation is not independent randomized evidence or cirrhosis/liver-death prevention; shared participants remain one study.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

### [5] Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels.

**Shows:** Lifestyle-versus-education paired biopsies show weight-associated changes in ceramide expression/serum measures.

**Does not show:** Shares the primary lifestyle trial; molecular correlation is not ceramide necessity or an additional independent histology efficacy line.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [6] Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.

**Shows:** Exercise at maintained weight reduced hepatic triglyceride and visceral fat in 24 biopsy-confirmed NASH adults over 12 weeks, with inflammation/fibrosis markers unchanged.

**Does not show:** No repeated biopsy and below registered 24-week gate; liver-fat improvement cannot establish steatohepatitis or fibrosis reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [7] Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease.

**Shows:** Pooled exercise trials increased odds of a 30% MRI-fat reduction with little weight loss and improved fitness.

**Does not show:** The endpoint is an imaging surrogate, not measured histologic response or fibrosis improvement; pooled parents do not create independent clinical histology lines.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [8] Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial.

**Shows:** Twelve-week HIIT in 23 NAFLD adults reduced liver fat and improved selected cardiac/body measures, with glucose-control nulls.

**Does not show:** No paired NASH histology and short follow-up; fat reduction does not imply ballooning/inflammation reversal or hard liver outcomes.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [9] Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.

**Shows:** Six-month Mediterranean diet/lifestyle counseling reduced weight and selected ALT/stiffness measures versus written advice.

**Does not show:** Ultrasound NAFLD and elastography are not biopsy-confirmed MASH resolution/fibrosis; bundled diet, exercise and sleep cannot isolate weight mediation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [10] Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial.

**Shows:** Fasting-plus-exercise reduced liver fat versus exercise/control in an 80-person three-month trial, with several metabolic and fibrosis-score nulls.

**Does not show:** No biopsy MASH and short exposure; no clear added benefit over fasting alone, and scores cannot establish fibrosis reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [11] A multidisciplinary nutritional-behavioral intervention improves weight loss and liver-related outcomes in patients with metabolic dysfunction-associated steatotic liver disease: A randomized controlled trial.

**Shows:** An 18-month multidisciplinary MASLD trial improved adherence, weight and liver imaging/stiffness and reported fewer acute cardiovascular events.

**Does not show:** No paired MASH biopsy or hard hepatic endpoint is established from the abstract; cardiovascular events are distinct from cirrhosis/liver-death prevention and component mediation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3, SC4.

### [12] Isocaloric-restricted traditional Jiangnan diet combined with physical exercise on non-alcoholic fatty liver disease: a randomized controlled trial.

**Shows:** A 228-person diet/exercise trial found liver imaging/stiffness differences despite no between-group weight advantage.

**Does not show:** FibroScan improvements are not histologic fibrosis reversal; MRI NAFLD differs from registered biopsy-MASH and diet components may act independently of weight.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [13] Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD).

**Shows:** Twelve-person uncontrolled multidisciplinary program reduced weight, liver tests and noninvasive fat estimates over three months.

**Does not show:** No control, biopsy or registered horizon; association does not establish steatohepatitis reversal or clinical events.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [14] Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.

**Shows:** Viusid-plus-diet/exercise versus diet/exercise in 60 biopsy-NAFLD adults improved NAS more with supplement; both groups improved histology.

**Does not show:** Randomization isolates supplement addition rather than lifestyle efficacy; between-group fibrosis difference was nonsignificant, and shared cointerventions cannot prove weight necessity.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [15] A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.

**Shows:** Ten biopsy-NASH adults receiving orlistat plus dietary counseling showed observed weight/metabolic and selected paired-biopsy improvements over six months.

**Does not show:** Uncontrolled drug/lifestyle combination and achieved-loss subgroup cannot establish assigned lifestyle causality or universal fibrosis reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [16] Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study.

**Shows:** Balloon versus sham on matched diet/exercise lowered BMI and NAS in an 18-person six-month pilot.

**Does not show:** No inflammation, ballooning or fibrosis score change; a NAS difference cannot automatically be called full MASH resolution, and device addition is a distinct intervention.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [17] Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial.

**Shows:** ESG versus sham with matched lifestyle in 40 biopsy-MASH adults increased loss and reduced steatosis/stiffness at 72 weeks.

**Does not show:** Between-group NAS and fibrosis were null; achieved-over-10% NAS subgroup is nonrandomized and does not rescue broad histology/fibrosis claims.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [18] Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial.

**Shows:** MAESTRO secondary analysis associates achieved weight loss with larger resmetirom histology/imaging responses across selected diabetes-drug backgrounds.

**Does not show:** Shared primary trial and nonrandomized achieved weight/background treatment cannot isolate lifestyle mediation or add an independent drug causal line.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [19] Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial.

**Shows:** Nine-month oligofructose pilot in 14 biopsy-NASH adults improved NAS/steatosis independent of weight loss.

**Does not show:** Steatosis-driven score change and small prebiotic exposure do not establish lifestyle-loss necessity or verified inflammation/ballooning reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [20] HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study.

**Shows:** HTD1801 hamster biopsy benefit accompanies an original human secondary analysis showing MRI/serum response proxies in presumed MASH.

**Does not show:** Human histology was not measured; model results and predictive response criteria cannot establish patient MASH/fibrosis reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [21] The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease.

**Shows:** Curcumin-plus-lifestyle trial showed several within-group changes but no superiority for main metabolic/steatosis measures versus lifestyle-placebo.

**Does not show:** No paired biopsy or isolated lifestyle randomization; within-group fibrosis-score improvement is not a between-group clinical reversal effect.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [22] Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.

**Shows:** Silymarin/vitamin-E-plus-diet versus diet reduced selected noninvasive indices in baseline biopsy-NAFLD over three months.

**Does not show:** No follow-up biopsy and distinct exercise/supplement cointerventions; post-loss subgroup indices cannot establish fibrosis or histologic reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [23] Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

**Shows:** ESSENCE randomized semaglutide 2.4 mg weekly in biopsy-MASH; the first 800 at 72 weeks had greater histologic resolution and fibrosis improvement than placebo.

**Does not show:** Distinct drug exposure and interim histology do not establish lifestyle mediation or the ongoing 240-week clinical-event result; pain endpoint was null and GI events more common.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4.

### [24] Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

**Shows:** In 71 compensated F4 patients, 48-week semaglutide reduced weight and MRI fat but did not significantly improve biopsy fibrosis, NASH resolution or component scores.

**Does not show:** Selected original Methods/Results confirm stage-specific dissociation; absence of decompensation in this small short trial is not prevention proof and biopsy availability differed by arm.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph7, 1:Methods:paragraph10, 1:Methods:paragraph11, 1:Methods:paragraph15, 2:Results:paragraph5, 2:Results:paragraph8, 2:Results:paragraph9, 2:Results:paragraph11, 2:Results:paragraph15, 2:Results:paragraph24. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4.

### [25] A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

**Shows:** A 320-person daily semaglutide biopsy trial found greater NASH resolution at the highest dose but a nonsignificant fibrosis endpoint at 72 weeks.

**Does not show:** Daily dosing and drug action differ from lifestyle; fibrosis null cannot be replaced by steatosis or posthoc continuous-image improvement.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [26] Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.

**Shows:** A prospective bariatric cohort found substantial observed NASH resolution and fibrosis regression in available five-year biopsies.

**Does not show:** Surgery is distinct from lifestyle, follow-up exceeds the registered primary horizon, and selective repeat biopsies without random control limit causal and hard-event inference.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4.

### [27] Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.

**Shows:** SPLENDOR associated bariatric surgery with lower long-term major adverse liver and cardiovascular events in biopsy-fibrotic NASH.

**Does not show:** Weighted observational surgery comparison is not randomized lifestyle-event evidence; raw and adjusted risk differences are different estimands, and perioperative deaths remain relevant.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

### [28] Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.

**Shows:** Semaglutide in an MRI-defined NAFLD trial reduced liver fat without a significant liver-stiffness benefit.

**Does not show:** MRI fat and stiffness are distinct from actual inflammation, ballooning and fibrosis biopsy; a drug trial does not isolate lifestyle or weight mediation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [29] Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.

**Shows:** BRAVES randomized 288 participants and found more one-year NASH resolution with either bariatric operation than lifestyle plus best medical care.

**Does not show:** The lifestyle-arm response rate lacks an untreated comparator; surgery and cointerventions differ, and operative serious adverse events cannot be omitted.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [30] Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.

**Shows:** A 24-week semaglutide combination trial improved selected MRI-fat and metabolic measures with additional experimental drugs.

**Does not show:** Combination components and noninvasive endpoints cannot establish lifestyle or human biopsy fibrosis reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [31] Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.

**Shows:** AI reassessment of the semaglutide biopsy trial detected continuous histologic signals beyond categorical endpoints.

**Does not show:** Shares the original daily semaglutide parent; a posthoc continuous-image measure does not overturn its prespecified categorical fibrosis null or supply a new causal study.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [32] A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.

**Shows:** MAESTRO-NASH found greater 52-week MASH resolution and fibrosis improvement with resmetirom than placebo in 966 participants.

**Does not show:** A liver-directed drug establishes its own biopsy efficacy rather than assigned lifestyle efficacy or hard clinical-event prevention.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [33] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

**Shows:** SYNERGY-NASH randomized 190 participants and found greater 52-week MASH resolution and fibrosis improvement with tirzepatide, using its missing-biopsy analysis.

**Does not show:** Drug action is distinct; 157 had follow-up biopsies and an indexed erratum remains linked, whose correction details have not been separately examined.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum In: PMID41880634. Subclaims: SC1, SC2, SC3.

### [34] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

**Shows:** LEAN found greater 48-week NASH resolution and less fibrosis progression with liraglutide in a small randomized paired-biopsy trial.

**Does not show:** Only 45 of 52 had endpoint biopsies; drug and lifestyle mediators are not separated, and less progression is not universal fibrosis reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [35] A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

**Shows:** NATIVE found positive activity and selected resolution/fibrosis endpoints with high-dose lanifibranor over 24 weeks despite weight gain.

**Does not show:** Lower-dose primary significance differed; the result challenges weight-loss necessity for every therapy without refuting lifestyle sufficiency.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [36] Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

**Shows:** The randomized phase-2 resmetirom trial reduced its MRI-fat primary endpoint over 36 weeks in biopsy-confirmed NASH.

**Does not show:** The examined abstract does not supply complete secondary biopsy-component evidence; MRI response is not hard-event prevention or isolated weight mediation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [37] Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study.

**Shows:** A 124-person biopsy-MASH trial reported better histologic improvement with vitamin E 300 mg than placebo.

**Does not show:** Drug-specific benefit does not prove assigned lifestyle efficacy, and the abstract does not specify enough timing/component detail to reconstruct every registered histology criterion.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [38] Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

**Shows:** REGENERATE reported a positive 18-month fibrosis endpoint with higher-dose obeticholic acid while NASH-resolution endpoints were nonsignificant.

**Does not show:** Fibrosis and active steatohepatitis can dissociate; indexed errata remain attached and their details were not independently audited; pruritus and clinical-event uncertainty matter.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum In: PMID32738952; Erratum In: PMID34147150. Subclaims: SC2, SC3, SC4.

### [39] Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

**Shows:** Pioglitazone versus placebo on matched hypocaloric diet improved NASH histology in 101 prediabetic/diabetic adults over 18 months despite weight gain.

**Does not show:** The randomized addition is pioglitazone, not diet; weight gain counters universal weight-loss necessity without erasing lifestyle efficacy.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [40] Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.

**Shows:** A target-trial emulation associated some GLP1-based therapies with fewer major adverse liver outcomes over two years, with drug-specific differences.

**Does not show:** EHR confounding and exposure/diagnosis ascertainment remain; it is not an actual randomized event trial or lifestyle-to-event mediation test.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

### [41] Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.

**Shows:** SYNERGY-NASH posthoc responder and mediation analyses associated achieved weight/metabolic changes with biopsy response.

**Does not show:** Shares the parent trial and uses completers/responders; statistical mediation does not randomize weight or establish a necessary isolated mediator.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [42] Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.

**Shows:** A MAESTRO-NASH F2-F3 analysis reports stage-defined histologic benefits of resmetirom.

**Does not show:** Baseline stage is valid context but the participants share the primary parent and do not create an independent lifestyle or drug causal line.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [43] Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.

**Shows:** FLINT posthoc analysis associated weight change with additive histology responses during obeticholic-acid treatment, with adverse metabolic changes.

**Does not show:** This is a different OCA parent from REGENERATE; achieved weight is nonrandomized and does not isolate lifestyle causality or weight necessity.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [44] Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial.

**Shows:** A 165-person six-month LCHF versus HCLF diabetes trial improved weight and glycemia more with LCHF but found no between-group liver-biopsy NAFLD difference.

**Does not show:** Not restricted to baseline MASH and no intentional weight-loss assignment; metabolic or weight improvement is not automatic histologic reversal, and benefits waned after diet discontinuation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [45] The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.

**Shows:** A small biopsy-NAFLD crossover found Mediterranean-diet MRI-fat and insulin-sensitivity improvement without different weight loss.

**Does not show:** Six-week periods and fat endpoints do not satisfy 24-week paired MASH histology; diet composition may act separately from weight change.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [46] Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH.

**Shows:** A small randomized ten-month energy-restriction/HIIT trial reported treatment improvements in inflammation, ballooning and steatohepatitis, while mean fibrosis remained unchanged.

**Does not show:** Actual Methods/Results define clinical histologic resolution; Results report 9 treatment and 0 control resolutions (final sample 16 and 8), reconcilable with eight treated ballooning-to-0 reductions because entry required NAS of at least 4 rather than ballooning of at least 1; component changes are reported within arm without a printed between-group test, controls entered with higher MRS liver fat (24% versus 15%), and bundled treatment and correlational mediators preclude isolated weight causality.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS and METHODS:paragraph0, 1:MATERIALS and METHODS:paragraph1, 1:MATERIALS and METHODS:paragraph4, 2:RESULTS:paragraph0, 2:RESULTS:paragraph1, 2:RESULTS:paragraph4, 2:RESULTS:paragraph5. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [47] A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease.

**Shows:** A four-arm diet/exercise NAFLD-prediabetes trial linked liver-fat and microbiome changes in 85 of 115 completers over about nine months.

**Does not show:** No actual follow-up MASH histology or randomized microbial mediator; completer associations cannot establish microbiome necessity or fibrosis reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [48] Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial.

**Shows:** TANGO compared diet strategies in 88 Chinese women and found short-term fat/weight responses.

**Does not show:** Twelve-week noninvasive outcomes and restricted sex/context do not establish the registered adult MASH histology response.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [49] Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity.

**Shows:** A 39-person two-month very-low-calorie ketogenic diet study reduced MRI liver fat and weight.

**Does not show:** Short exposure, noninvasive fat and different dietary composition cannot establish inflammation/ballooning or fibrosis reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [50] Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial.

**Shows:** A 40-boy randomized free-sugar-restriction trial reduced liver fat over eight weeks in adolescent NAFLD.

**Does not show:** Children, short follow-up and MRI-fat outcome are outside registered adult MASH biopsy scope; an indexed erratum remains linked rather than counted as an original study.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum In: PMID31386114. Subclaims: SC1, SC2.

### [51] Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.

**Shows:** LEAN's 14-person mechanism substudy examined clamp and cellular changes during 12 weeks of liraglutide.

**Does not show:** Shares the LEAN treatment platform; physiological and cell findings do not establish isolated weight mediation, a new clinical histology line or the registered horizon.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [52] Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.

**Shows:** Ipragliflozin versus control in a small 72-week diabetes/NAFLD paired-biopsy trial reported more fibrosis improvement and NASH resolution.

**Does not show:** A distinct drug in a mixed baseline NAFLD population is not a lifestyle causal comparison; incomplete follow-up biopsies and small numbers limit transfer.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [53] Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.

**Shows:** MAESTRO-NASH reported health-related quality-of-life patterns related to histologic response.

**Does not show:** Shares the parent and response-defined analysis; functional association does not establish liver-death prevention or independent efficacy.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

### [54] Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.

**Shows:** A small selected resmetirom extension documented continued noninvasive hepatic/metabolic responses out to 72 weeks.

**Does not show:** An open-label completer extension shares its phase-2 parent, lacks concurrent randomized control and cannot establish lifestyle or event prevention.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [55] GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study.

**Shows:** A matched older-adult MASLD EHR cohort associated GLP1 initiation with lower decompensation and mortality hazards but no lower MACE hazard.

**Does not show:** Coded diagnoses, residual prescribing confounding and varying follow-up remain; drug associations cannot prove lifestyle or surrogate-to-clinical causality.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

### [56] Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.

**Shows:** A 64-person pemvidutide extension retained assigned doses and showed greater MRI-fat and weight reductions at 24 weeks.

**Does not show:** Selected extension completers and imaging endpoints do not establish paired-biopsy MASH/fibrosis or isolate weight versus direct glucagon action.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [57] Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.

**Shows:** MAESTRO-NAFLD-1 randomized resmetirom in presumed NASH and documented safety plus MRI-fat/lipid/stiffness responses over 52 weeks.

**Does not show:** Different trial from biopsy MAESTRO-NASH; presumed disease and noninvasive endpoints cannot independently prove MASH histologic reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [58] Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.

**Shows:** Lanifibranor in 38 diabetes/MASLD adults improved hepatic fat and clamp insulin sensitivity over 24 weeks despite modest weight gain.

**Does not show:** A different metabolic trial lacks the registered paired-biopsy MASH endpoint; positive fat/glycemia cannot be promoted to fibrosis or hard liver events.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [59] Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.

**Shows:** Resmetirom in biopsy-confirmed diet-induced mouse NASH improved fat/activity and fibrogenic measures without changing weight.

**Does not show:** Forced diet/model exposure and liver-directed drug do not establish endogenous human weight mechanisms or assigned lifestyle response; alpha-SMA/gene changes are not universal clinical fibrosis proof.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [60] Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease.

**Shows:** Three biopsy-NASH patients showed lower hepatic rpS6 phosphorylation after a 20-week exercise intervention.

**Does not show:** Uncontrolled tiny marker study is below the registered duration and does not establish pathway necessity, MASH resolution or actual fibrosis reversal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [61] Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial.

**Shows:** Eckard et al. 2013 randomized 56 adults with biopsy-proven NAFLD to standard care or one of three diet/exercise arms for six months with repeat biopsy; NAS improved in the 41 completers (88% with NASH) as a whole (p < 0.001) with no difference between arms, standard care included (p = 0.31).

**Does not show:** A randomized lifestyle-versus-standard-care paired-biopsy contrast was null; mixed NAFLD/NASH entry, completer analysis and small arms limit it, NAS is a composite rather than current resolution criteria, and it does not refute the positive SC2 trial.

**Access/status:** PubMed abstract and record metadata examined during the 2026-11-02 adversarial pass (added on that pass's finding WL-2); no complete-paper or supplement audit claimed. none_found. Subclaims: SC2.